导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.49% | 2941/4773 |
| 近一周 | -2.20% | 1477/5462 |
| 近一月 | -4.22% | 2308/5421 |
| 近一季 | -7.81% | 2542/5209 |
| 近半年 | -3.35% | 2181/4920 |
| 近一年 | -0.14% | 2674/4366 |
| 近两年 | 44.31% | 1673/2954 |
| 近三年 | 26.35% | 1216/2253 |
| 成立以来 | 59.32% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.65% 3331/4961 |
11.90% 2270/5312 |
- - |
- - |
| 2025 | 19.23% 2236/4813 |
-1.04% 2549/3635 |
2.11% 1854/4076 |
17.89% 2405/4524 |
0.08% 2233/4813 |
| 2024 | 17.07% 731/3463 |
2.77% 712/2808 |
-1.17% 963/3014 |
16.85% 1333/3129 |
-1.36% 1664/3463 |
| 2023 | -9.27% 1143/2656 |
4.32% 983/2280 |
-3.93% 972/2385 |
-2.96% 805/2515 |
-6.71% 1884/2655 |
| 2022 | -19.35% 838/2207 |
-13.81% 844/1919 |
6.66% 642/2016 |
-13.71% 956/2113 |
1.66% 1186/2208 |
| 2021 | 0.17% 726/1822 |
-2.48% 652/1255 |
6.01% 774/1330 |
-4.83% 739/1466 |
1.81% 793/1822 |
| 2020 | 37.00% 385/1250 |
-8.77% 630/1028 |
14.00% 577/1067 |
15.82% 193/1164 |
13.73% 334/1184 |
| 2019 | 38.62% 305/1092 |
27.14% 357/754 |
0.26% 184/804 |
1.24% 422/850 |
7.42% 437/918 |
| 2018 | -21.29% 208/834 |
- - |
- - |
- - |
-11.79% 348/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 汇添富沪深300指数A(LOF)A VS. 长安沪深300非周期A(740101) |